Latent tuberculosis infection (LTBI) is a subclinical mycobacterial infection defined on the
basis of cellular immune response to mycobacterial antigens. The tuberculin skin test (TST) …

In this review we discuss recent progress in the development, testing, and clinical evaluation
of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has …

Tuberculosis control relies on the identification and preventive treatment of individuals who
are latently infected with Mycobacterium tuberculosis. However, direct identification of latent …

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. As a
result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate in …

With 1.4 million deaths and 8.7 million new cases in 2011, tuberculosis (TB) remains a
global health care problem and together with HIV and Malaria represents one of the three …

New approaches to control the spread of tuberculosis (TB) are needed, including tools to
predict development of active TB from latent TB infection (LTBI). Recent studies have …

Mycobacterium tuberculosis infects one third of the human world population and kills
someone every 15 seconds. For more than a century, scientists and clinicians have been …

Tuberculosis (TB) poses a great challenge to immunologists, as it represents a chronic
infection characterized by persistence of the pathogen despite development of antigen …

Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell
transplantation. The identification of candidates for preventive chemotherapy is an effective …

Mycobacterium tuberculosis survives in latently infected individuals, likely in a
nonreplicating or dormancy-like state. The M. tuberculosis DosR regulon is a genetic …